Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells by Cánovas, Verónica et al.
Oncotarget59165www.impactjournals.com/oncotarget
Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-
resistance and survival of castration resistant prostate cancer 
cells
Verónica Cánovas1, Yolanda Puñal1, Valentina Maggio1, Enric Redondo1, Mercedes 
Marín2, Begoña Mellado2, Mireia Olivan1, Matilde Lleonart3, Jacques Planas1,4, Juan 
Morote1,4 and Rosanna Paciucci1
1Biomedical Research Group of Urology, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
2Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research 
Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain
3Biomedical Research in Cancer Stem Cells, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
4Deparment of Urology, Vall d’Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
Correspondence to: Rosanna Paciucci, email: rosanna.paciucci@vhir.org
Keywords: PTOV1, docetaxel resistance, prostate cancer, metastasis, apoptosis
Received: November 09, 2016    Accepted: June 19, 2017    Published: July 22, 2017
Copyright: Cánovas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, 
first described in prostate cancer, was reported as overexpressed and significantly 
correlated with poor survival in numerous tumors. Here, we investigated the role of 
PTOV1 in prostate cancer survival to docetaxel and self-renewal ability. Transduction 
of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell 
survival after docetaxel exposure and induced docetaxel-resistance genes expression 
(ABCB1, CCNG2 and TUBB2B). In addition, PTOV1 induced prostatospheres formation 
and self-renewal genes expression (ALDH1A1, LIN28A, MYC and NANOG). In contrast, 
Du145 and PC3 cells knockdown for PTOV1 significantly accumulated in the G2/M 
phase, presented a concomitant increased subG1 peak, and cell death by apoptosis. 
These effects were enhanced in docetaxel-resistant cells. Analyses of tumor datasets 
show that PTOV1 expression significantly correlated with prostate tumor grade, drug 
resistance (CCNG2) and self-renewal (ALDH1A1, MYC) markers. These genes are 
concurrently overexpressed in most metastatic lesions. Metastases also show PTOV1 
genomic amplification in significant co-occurrence with docetaxel-resistance and self-
renewal genes. Our findings identify PTOV1 as a promoter of docetaxel-resistance and 
self-renewal characteristics for castration resistant prostate cancer. The concomitant 
increased expression of PTOV1, ALDH1A1 and CCNG2 in primary tumors, may predict 
metastasis and bad prognosis.
INTRODUCTION
Prostate cancer is the most common male malignancy 
and the second leading cause of death for cancer in men 
of western Countries [1]. The majority of newly diagnosed 
localized tumors are successfully treated by surgery. 
Patients with metastatic prostate cancer undergo androgen 
deprivation therapy (ADT), very effective in reducing 
prostate tumor and metastatic growth. However, progression 
to a castration-resistant prostate cancer (CRPC) eventually 
occurs [2, 3]. Docetaxel, a taxol derived drug that prevents 
microtubule de-polymerization and mitotic division, was 
the standard treatment in US for CRPC patients until 2010 
[4]. More recently, docetaxel combined with androgen 
deprivation therapy have been used at earlier stages to 
improve the outcome for men with metastases at first 
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presentation [5–7], but unfortunately in most cases it results 
in the development of a very aggressive resistant cancer.
PTOV1 was previously demonstrated to be pro-
oncogenic in prostate cancer [8–11]. The protein is 
strongly expressed in primary tumors and metastatic 
lesions [9–11]. Its detection in premalignant lesions of 
high grade prostate intraepithelial neoplasia (HGPIN) 
is helpful to identify patients with significantly higher 
probability to develop prostate cancer [12, 13]. PTOV1 
is overexpressed and significantly associated to a high 
grade of malignancy, increased proliferation, and 
unfavorable prognosis in a number of other neoplasias 
[13–18]. Its expression induces spheroid formation 
in vitro, tumor growth, invasion and metastasis of 
CRPC cells [10, 11]. Mechanistic studies have shown 
that PTOV1 cytoplasmic localization is associated 
to activation of translation of a subset of mRNAs 
through the interaction with RACK1 and ribosomes, 
leading to a specific increased synthesis of the c-Jun 
oncogene [10]. In turn, c-Jun was shown to promote 
SNAI1 transcription and the activation of an epithelial-
mesenchymal transition (EMT) program, leading to 
tumor growth and metastasis [10]. In the nucleus, 
PTOV1 acts as a transcriptional repressor of HES1 and 
HEY1 genes, two main targets of the Notch receptor, thus 
revealing its oncogenic function in counteracting the 
tumor suppressor action of Notch signaling in advanced 
prostate cancer [11]. PTOV1 is a transcriptional repressor 
of the DKK1 gene, an action that triggers the activation 
of the Wnt/β-catenin signaling and tumor progression in 
breast cancer cells [16], and of the retinoic acid receptor 
(RARβ), favoring cell resistance to retinoic acid [19]. A 
recent review about the known oncogenic mechanisms of 
PTOV1 in tumors is available [20].
The resistance to docetaxel in treated tumors is 
associated to the expression of alternative β-tubulin 
isoforms, genes encoding for drug efflux pumps, and 
survival factors [21–23]. In addition, resistant metastatic 
growth has been associated to rare populations of slow 
growing cells within tumors identified as cancer stem 
cells (CSCs) that have intrinsic resistance to therapeutic 
stress [24–26]. Recent data suggest that taxanes can also 
affect androgen receptor (AR) signaling by inhibiting 
ligand-induced AR nuclear translocation and downstream 
transcriptional activation of its target genes and 
confirming a role for microtubules in AR trafficking [27]. 
However, AR nuclear translocation and signaling was 
not inhibited in cells with acquired β-tubulin mutations, 
that prevent taxanes-induced microtubule stabilization 
[28]. In addition, c-Jun, SNAI1, and NOTCH2/Hedgehog 
pathways have been implicated in the development 
of resistance to docetaxel or paclitaxel [23, 29, 30]. 
However, despite the intense research, the mechanisms of 
prostate cancer resistance to docetaxel are not completely 
understood and more investigations are required to design 
targeted therapies able to overcome its insurgence.
Here, our findings reveal a critical function for 
PTOV1 in the activation of genes implicated in the 
acquisition of resistance to docetaxel and the appearance 
of a stemness-like phenotype. These results are confirmed 
by analyses of datasets from human prostate tumors 
and reveal a specific and significant direct correlation 
of PTOV1 with ALDH1A1 and CCNG2. These findings 
identify PTOV1 as a novel potential therapeutic target for 
patients with metastatic prostate cancer.
RESULTS
PTOV1 promotes docetaxel resistance in CRPC 
cells
Increased mRNA and protein levels of PTOV1 were 
shown to correlate with prostate cancer progression [10, 
11] and to promote CSCs-like properties [11, 16]. Here, 
we investigated whether its overexpression in prostate 
cancer cells is associated to the acquisition of resistance 
to a therapeutic stress. Thus, PTOV1 expression was 
analyzed in Du145 and PC3 prostate cancer cells rendered 
resistant to docetaxel in vitro as representative models 
of CRPC progression to a docetaxel resistant (DR) stage 
[31]. DR-Du145 and DR-PC3 cells show an evident 
mesenchymal phenotype (Figure 1A), as previously 
described [31, 32], a very significant decrease in epithelial 
markers, and overexpression of genes implicated in 
the acquisition of drug resistance, previously reported 
in taxanes resistant cells [31–36]. In contrast to its low 
levels in benign prostate derived RWPE1 cells, PTOV1 is 
strongly expressed in most prostate carcinoma cell lines 
(Supplementary Figure 1A). Both DR-Du145 and DR-PC3 
cell variants have a consistently increased protein levels 
for PTOV1 compared with parental docetaxel sensitive 
(DS) cells (Figure 1B and Supplementary Figure 1B), 
and a significant increase in RNA levels is observed 
in DR-Du145 but not in DR-PC3 cells (Figure 1C). 
To address whether translation rates may contribute to 
increase PTOV1 protein levels in DR cells, we analyzed 
the levels of PTOV1 transcripts more actively translated 
by studying the amount of mRNA loaded on polysomes 
(Supplementary Figure 2A). No significant differences 
are found comparing the total (DR-T) and polysomes-
associated mRNA levels (DR-P) in DR cells compared 
to control DS cells, suggesting that the higher protein 
expression observed in DR cells is not contributed by 
an enhanced protein synthesis. In addition, although a 
significant increase in PTOV1 protein stability is detected 
in cycloheximide (CHX)-treated DR-Du145 cells, no 
significant differences were detected in DR-PC3 cells, 
suggesting that the mechanisms underlying the higher 
PTOV1 protein expression in DR cells need to be explored 
further (Supplementary Figure 2B).
To establish if the increased PTOV1 expression 
in DR cells has a role in the acquisition of resistance to 
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docetaxel, DS cells were transduced with a lentivirus 
encoding HAPTOV1, or a control lentivirus encoding the 
GFP gene (Figure 2A; Supplementary Figure 3A). Both 
the endogenous and the ectopic PTOV1 show similar 
distributions in the membrane, cytoplasm and nucleus 
(Supplementary Figure 3B). Transduced cells were treated 
with increasing doses of docetaxel for 48 h (Du145) and 
72 h (PC3). The expression of PTOV1 was associated to a 
significantly augmented IC50 to docetaxel in both cell lines, 
compared to control DS-GFP cells (Figure 2B). The IC50 
for docetaxel in resistant Du145 and PC3 cells transduced 
with control lentivirus are also shown for comparison. 
To elucidate the molecular mechanisms implicated in 
this PTOV1-mediated chemo resistance, a battery of 
genes previously implicated in docetaxel resistance were 
analyzed in PTOV1-overexpressing cells [22, 23, 31, 34]. 
Figure 2C shows that PTOV1 significantly induces the 
expression of CCNG2, ABCB1, TUBB4A and TUBB2B 
genes, supporting its action in promoting the resistance 
to docetaxel. The expression of PTOV1 significantly 
associated with the levels of the multidrug transporter 
ABCB1 (Supplementary Figure 3C).
Because upregulation of ABCB1 and TUBB2B were also 
observed when PTOV1 was overexpressed in the AR-positive 
LNCaP cells (Supplementary Figure 3D), the PTOV1-induced 
upregulation of these genes may be AR independent.
In contrast, ectopic PTOV1 in DS-Du145 and DS-
PC3 cells exposed to cabazitaxel, a second generation 
of taxanes synthesized to overcome the resistance to 
docetaxel, did not produce significant changes in the 
cells sensitivity to this drug, indicating the specificity of 
PTOV1 in promoting resistance to docetaxel in CRPC 
cells (Supplementary Figure 4) [37]. Results also suggest 
that the induction of ABCB1 expression might be a 
relevant part of the mechanism by which PTOV1 confers 
cells with resistance to docetaxel.
PTOV1 promotes the acquisition of self-
renewing properties in CRPC cells
The significant association between PTOV1 and 
ABCB1 transporter expression, a protein also implicated in 
the modulation of the stemness phenotype in cancer cells 
[38], is in agreement with previous data showing PTOV1 
promoting self-renewing properties of prostate and breast 
cancer cells [11, 16]. The use of sphere-forming assays 
provides a widely recognized in vitro method for the 
identification and characterization of CSCs [39]. Thus, we 
investigated whether the role of PTOV1 in the resistance 
to docetaxel is associated to the activation of self-renewing 
characteristics in prostate cancer cells by analyzing the 
effects of the overexpression and knockdown of PTOV1 
Figure 1: PTOV1 is overexpressed in docetaxel resistant CRPC cell lines. (A) Phase contrast images of docetaxel sensitive 
(DS) and resistant (DR) Du145 and PC3 cells in culture. Size bar, 64 μm. Images were acquired with an inverted microscope (BX61, 
Olympus). (B) A representative immunoblot shows the expression of endogenous PTOV1 in Du145 and PC3 cells. The graph below shows 
the average of expression of PTOV1 from three independent immunoblots, two of which are shown in Supplementary Figure 1B. (C) 
Endogenous mRNA levels of PTOV1 (mean ± S.D.) determined by real-time RT-PCR.
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in the prostatosphere forming capacities of docetaxel-
sensitive cells. Figure 3A and 3B show that DS-HAPTOV1 
cells have a significant increase in the sphere-forming 
efficiency in comparison to DS-GFP control cells, 
confirming the PTOV1 promoted induction of a stemness-
like phenotype. In Du145 cells, the overexpression of 
Figure 2: The ectopic expression of PTOV1 in DS Du145 and PC3 cell lines promotes docetaxel resistance. (A) DS-
Du145 or DS-PC3 cells transduced with a lentivirus encoding the fusion protein HA-PTOV1 or a control lentivirus encoding the GFP 
protein, were analyzed by western blotting using first antibodies to Hemoagglutinin (HA) to detect PTOV1, then antibodies to actin. The 
double bands in the HAPTOV1 lanes visible in the second panel (actin), are the signal left from the anti-HA antibody. (B) Transduced cells 
were treated with increasing doses of docetaxel for 48 h (Du145) or 72 h (PC3) and cell viability was analyzed by crystal violet. Control 
docetaxel resistant GFP cells (DR GFP) are shown for reference. A representative experiment of three performed is shown. (C) Real-time 
RT-PCR of the genes indicated analyzed in DS-HAPTOV1 cells compared to controls (DS-GFP). Results are the mean of three independent 
experiments performed in triplicates and are shown as the mean ± S.D; p-value: *< 0.05; **< 0.01; *** < 0.005. nM, nanomolar.
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Figure 3: PTOV1 increases the tumorigenic capacity of Du145 and PC3 cells in vitro and induces the expression of self-
renewal genes. (A) Phase contrast images, and (B) quantification of prostatospheres from cells transduced with lentiviruses encoding 
HAPTOV1 or GFP, with lentiviruses carrying different shRNA sequences (sh1439, sh1401) to knockdown PTOV1, or a control knockdown 
lentivirus carrying non-specific sequences (shCTL). Images in A were acquired with an inverted microscope (BX61, Olympus). SFE: 
Sphere Forming Efficiency (number of spheres formed /1000 cells). (C) Relative mRNA levels by real-time RT-PCR of the genes associated 
to self-renewal in DS-HAPTOV1 and DS-GFP cells. All experiments were performed in triplicate. Results are shown as the mean ± S.D; 
p-value: *< 0.05; **< 0.01; *** < 0.005.
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HAPTOV1 also associated to significantly increased levels 
of stemness genes LIN28A, ALDH1A1 and MYC, whereas 
in PC3 cells it associated to a significant expression of 
LIN28A, MYC, NANOG and POU5F1 genes (Figure 3C), 
in agreement with reports in breast cancer cells [16]. 
Significantly increased levels of LIN28A and MYC were 
also observed in LNCaP cells overexpressing HAPTOV1 
(Supplementary Figure 5A). Of note, the expression 
of PTOV1 is significantly associated with the levels of 
LIN28A in Du145 cells (Supplementary Figure 5B), 
indicating again its ability to induce a stemness phenotype 
and confirming previous observations [11, 16].
PTOV1 actions were previously described to be 
mediated in part through the activation of c-Jun protein 
synthesis [10] and Wnt/β-catenin signaling [16]. In 
Du145 cells the inhibition of JNK signaling significantly 
decreases ABCB1 expression, as previously described [40] 
(Supplementary Figure 6A). Regarding Wnt/ β-catenin 
signaling, these cells require Wnt3a conditioned medium 
(Wnt3a-CM) for its activation (Supplementary Figure 
6B). Wnt3a-CM upregulates ABCB1, ALDH1A1 and 
Wnt-target genes LEF1 and JUN, effects counteracted 
by the iCRT14 Wnt inhibitor, as previously observed 
[41–44] (Supplementary Figure 6B). The overexpression 
of PTOV1 significantly increased ABCB1 expression 
and, reversibly, this was significantly abolished by Wnt 
and JNK inhibitors, suggesting that PTOV1 action on 
this gene is mediated at least in part by these pathways 
(Supplementary Figure 6C). However, no inhibition 
of ALDH1A1 or LIN28A expression is observed in the 
presence of these inhibitors in PTOV1-overexpressing 
cells, suggesting a Wnt and JNK independent actions of 
PTOV1 (Supplementary Figure 6C).
The knockdown of PTOV1 induces G2/M cell 
cycle arrest and apoptosis of CRPC cells
As expected, the knockdown of PTOV1 by different 
short hairpin RNAs (Supplementary Figure 7A) provokes 
a striking and significant repressive effect in the cells 
sphere-forming efficiency (SFE) in comparison to control 
cells bearing an unrelated shRNA sequence (shCTL) 
(Figure 3A and 3B). These findings indicate a promoting 
action of PTOV1 in proliferation and/or survival of 
prostate cancer cells. Because docetaxel resistant 
prostate cancer cells show an increased expression of 
PTOV1 (Figure 1B), we have determined the effects of 
its knockdown using two different shRNAs directed to 
different sequences of the gene PTOV1, in both docetaxel 
sensitive and resistant cells (Supplementary Figure 7A 
and 7B). RNA and protein expression are efficiently 
downregulated by these shRNAs, as it is shown by real-
time PCR, Western blotting and immunofluorescence 
assays, the latter showing that downregulation of the 
protein is observed both in nucleus and cytoplasm 
(Supplementary Figure 7A-7D). Cell proliferation requires 
the expression of PTOV1 (Figure 4A). This impair in 
proliferation is translated in a significant increase in cell 
mortality, as shown by the Trypan blue exclusion assay 
(Figure 4B). These effects are enhanced in DR cells 
compared to DS cells, suggesting that resistant cells are 
more dependent on the expression of PTOV1. The use of a 
third shRNA (sh1397) corroborate that PTOV1 inhibition 
significantly affects cell proliferation and viability 
(Supplementary Figure 8). The decrease in PTOV1 levels 
induces a loss of reproductive integrity and inability to 
proliferate indefinitely, as shown by clonogenic assays 
(Supplementary Figure 9A and 9B). Of note, docetaxel 
resistant cells are more enriched with low-proliferative 
cells compared to sensitive cells, as it is evident from the 
more abundant formation of smaller colonies.
To investigate into the mechanisms of the 
requirement for PTOV1 in proliferation and/or survival, 
the cell cycle was analyzed by flow cytometry using 
propidium iodide. Figure 4C and 4D show that cells 
knockdowns for PTOV1 significantly accumulate in the 
G2/M phase in concomitance to a significant increase in 
the proportion of cells in the sub-G1 peak (Supplementary 
Figure 10A and 10B). In agreement with our previous 
observations, the accumulation of cells in the G2/M phase 
and the increase in the sub-G1 peak are more pronounced 
in DR cells (Figure 4C and 4D). The expression of cyclin 
B1 and the appearance of a cleaved PARP1 fragment in 
the knockdown cells, confirm the accumulation of cells 
in G2/M phase and the boost of apoptosis observed by 
cell cycle analyses (Figure 4E). These results support a 
requirement of the onco-protein PTOV1 for the survival 
of Du145 and PC3 prostate cancer cells.
Correlation of PTOV1 with ALDH1A1 and 
CCNG2 expression in metastatic prostate tumors
The expression of ALDH1A1, CCNG2 and MYC 
genes has been reported in aggressive prostate tumors 
[34, 45–48]. We examined the clinical significance of 
their upregulation and the association with PTOV1, 
highly overexpressed in aggressive prostate tumors 
(Supplementary Figure 11) as previously reported [10, 11], 
using publicly available database containing expression 
data, clinical and pathological information from prostate 
tumors of not-treated patients. These analyses reveal 
that primary prostate tumors show significantly higher 
expression of PTOV1, CCNG2 and MYC compared to 
benign tissue (GSE29079), and PTOV1 levels significantly 
correlate with CCNG2 and MYC mRNA levels (Figure 5A 
and 5B). As expected, patients with higher Gleason score 
have significantly higher levels of PTOV1 compared to 
patients with lower Gleason score (GSE46691) (Figure 5C) 
[9–11]. In this set of tumors, the expression of ALDH1A1 
and CCNG2 significantly correlates with prostate tumor 
aggressiveness (Figure 5C), in agreement with previous 
reports [45, 46]. In addition, a statistically significant 
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Figure 4: Downregulation of PTOV1 reduces proliferation and promotes G2/M cell cycle arrest and apoptosis in CRPC 
cells. Docetaxel sensitive (DS) and resistant (DR) Du145 and PC3 cells were knockdown for PTOV1 using short-hairpin (sh)1439 or 
sh1401. For coherence in the results and their interpretation, the experiments shown in this figure are from transduced cells at the same 
passage and same lentiviral preparation. Experiments were reproduced three times with different preparations of lentiviruses with similar 
results. (A) Histogram representing the proliferationof DS and DR Du145 and PC3 cells knockdown for PTOV1 compared to a control 
shRNA (shCTL). Proliferation was determined by crystal violet staining and absorbance at 595 nm after 96 h from lentiviral transduction. (B) 
Histogram representing the dead cells as assessed by the Trypan blue exclusion in knockdown cells after 96 h from lentiviral transduction. 
(C) Viable knockdown cells and controls as in A, were analyzed at 96 h by flow cytometry using propidium iodide. DS-Du145 cells treated 
with docetaxel at high concentration (1 μM) for 24 h were used as a control for G2/M arrest (CTL+). (D) Histograms representing the 
percentage of knockdown cells and controls found in each phase of the cell cycle from the experiment shown in C. (E) Immunoblots with 
the indicated antibodies showing the apoptosis caused by the knockdown of PTOV1 compared to controls from the same experiment shown 
above (A-D). p-value: *< 0.05; **< 0.01; *** < 0.005.
Oncotarget59172www.impactjournals.com/oncotarget
Figure 5: The expression of PTOV1, ALDH1A1, CCNG2 and MYC is significantly increased in human prostate tumors. 
(A) Box and whisker plots represent PTOV1, CCNG2 and MYC expression levels in prostate cancer compared to benign tissues from 
publicly available database (GSE29079; benign n=48; tumor n=47). (B) Significant statistical correlations between the expression of 
PTOV1 with CCNG2 and MYC in tumors analyzed in A. (C) Box and whisker plots representing PTOV1, ALDH1A1, CCNG2 and MYC 
expression in tumors with different Gleason as obtained from published prostate cancer gene expression profiles (GSE46691; Gleason 
score (GS) ≤6, n= 63; GS 7, n=271; GS 8, n=68; GS ≥9, n=143). (D) Significant statistical correlations between the expression of PTOV1 
with ALDH1A1 and CCNG2 in tumors analyzed in C. (E) Box and whisker plots representing PTOV1, ALDH1A1 and CCNG2 expression 
in tumors of patients that did not develop metastasis after radical prostatectomy (not met, n=333) compared to patients that did developed 
metastasis (met, n=212) (GSE46691). p-value: *< 0.05; **< 0.01; *** < 0.005.
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correlation exists between the expression of PTOV1 
with ALDH1A1 and CCNG2 (Figure 5D). However, the 
expression of MYC appears more significantly associated to 
the presence of carcinoma compared to benign tissue, than 
to the aggressiveness of the tumors according to this dataset. 
ALDH1A1, PTOV1 and CCNG2 transcripts levels are also 
significantly higher in primary prostatic adenocarcinomas 
of patients that after radical prostatectomy developed 
regional or distal metastasis (Figure 5E), suggesting their 
relationship with metastatic progression.
The correlation of the overexpression of PTOV1 with 
tumor progression and poor survival is confirmed in breast 
cancer [15, 16, 49]. We analyzed dataset from breast cancer 
tissues derived from patients treated with taxanes plus 
anthracyclines (GSE28844) [49] and found a significant 
increase of PTOV1 and CCNG2 mRNA levels in patients 
with lower Miller and Payne grade, corresponding to bad 
responders to that chemotherapy (Supplementary Figure 
12), reinforcing the potential role of PTOV1 and CCNG2 
in conferring resistance to chemotherapy with taxanes.
Analyses of RNA and DNA events from 
metastasis of castration resistant tumors
To study whether the associations of PTOV1 with 
self-renewal and docetaxel resistant genes found here 
are detectable in metastasis, we interrogated database 
containing information from metastatic lesions of prostate 
cancer patients [50–52]. Forty-nine metastatic lesions 
from 114 metastatic specimens had available data for RNA 
expression. Significantly, 96-100% of those lesions show 
concurrent increased expression of PTOV1, CCNG2, and 
MYC genes (Figure 6A). Similarly, concurrent expression 
is also found for ALDH1A1 gene in 33% of lesions.
Most alterations at the DNA level cover the complete 
amplification of PTOV1, amplified in 19% of metastatic 
specimens (Figure 6B), and include neighboring genes 
MED25 and AKT1S1 (Supplementary Figure 13). Frequent 
amplifications of MYC, ALDH1A1 and CCNG2 genes are 
also found (Figure 6B). In addition, highly significant co-
occurrence of alterations in DNA events is found among 
PTOV1, ALDH1A1, and MYC (Table 1).
Altogether, our findings indicate that the 
overexpression of PTOV1 in prostate cancer promotes the 
acquisition of resistance to chemotherapy with docetaxel 
that is parallel to the increase in self-renewal properties of 
prostate cancer cells. The significant increased expression 
of PTOV1 in primary prostate tumors may be predictor of 
metastastatic progression.
DISCUSSION
The oncogenic protein PTOV1 is associated to bad 
prognosis in several tumor types [8–11, 14, 15, 17, 18, 53–
Figure 6: Expression status and mutational profile of PTOV1 and related genes in metastatic lesions from CRPC 
patients. (A) Alteration of gene expression in 49 metastatic specimens from 35 CRPC patients (Beltran et al. [52]). (B) Copy number 
alteration and mutations in a cohort of 107 metastatic specimens from 77 patients from Beltran et al. [52]. Each bar represents one 
individual. Vertically aligned bars positions correspond to the same specimen.
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55]. In this work we provide evidences supporting its role 
in promoting the resistance to docetaxel and self-renewal 
abilities of prostate cancer cells. We further show that the 
expression of PTOV1, ALDH1A1 and CCNG2 found in 
primary prostate tumors of patients that had developed 
metastasis, is also found in a cohort of metastasic lesions, 
revealing that the above genes may be predictors of 
metastasis and bad prognosis.
Supporting previous findings of PTOV1 activity 
associated to more aggressive, potentially resistant stages 
[8–11], we show that docetaxel resistant prostate cancer 
cells express increased levels of PTOV1 concomitantly 
with genes associated to resistance [31, 33–36]. The 
PTOV1 induced expression in docetaxel sensitive cells, 
significantly increased their IC50 to this drug and activated 
the expression of ABCB1, TUBB4A, TUBB2B, MYC, and 
CCNG2 genes, demonstrating PTOV1 as a relevant factor 
to overcome toxicity to docetaxel. The PTOV1-promoted 
increase of ABCB1 expression, a drug transporter with 
high affinity for docetaxel but low affinity for cabazitaxel 
[37, 56], might explain its specific action in inducing 
cell resistance to docetaxel but not to cabazitaxel. The 
upregulation of ABCB1 might be a major mechanism 
of taxane resistance in the early response to docetaxel 
in advanced tumors, and in Du145, 22Rv1 and C4-2B 
prostate cancer cell lines [22, 23, 36, 57]. However, the 
expression of the protein ABCB1, not its RNA levels, 
was shown to correlate with the Gleason score in prostate 
tumors, possibly explained by a lower efficiency of RNA 
evaluation in those samples [58]. Recently, PTOV1 
was shown to increase the proportion of cells in the 
side population (SP) through the activation of Wnt/β-
catenin signaling in breast cancer [16]. Several studies 
described SP cells as CSC populations with upregulation 
of ABCB1 and a taxol-resistant phenotype [59–61]. 
These observations support our findings and suggest that 
PTOV1 promotes the acquisition of resistance to docetaxel 
and of stemness features partly through the expression 
of ABCB1. Although the specific increase of stemenss 
genes ALDH1A1 and LIN28A by PTOV1 does not 
appear mediated by Wnt and JNK signaling, the PTOV1 
promoted ABCB1 activation might be mediated by these 
pathways.
The concurrent overexpression of CCNG2 and 
ALDH1A1 found in the cell lines with the ectopic 
HAPTOV1 is confirmed in primary tumors of patients that 
developed metastasis and in metastatic lesions of CRPC 
patients. While ALDH1A1 and MYC genes were reported 
in metastasis of several tumor types and associated with 
poor prognosis [39, 45, 47, 62, 63], for CCNG2, a cell 
cycle checkpoint cyclin upregulated in response to DNA 
damage, the association to stemness was not clear. It 
was reported to have tumor suppressor functions in 
different neoplasias [64, 65], although, supporting our 
observations, CCNG2 positively associated with prostate 
cancer recurrence after radical prostatectomy [46]. 
CCNG2 induces microtubule bundling and stability, and 
contributes to resistance to chemotherapy, presumably by 
facilitating a delay in the transition from G1/S to G2/M 
phase that allow reorganization of microtubules and 
chromatin repairs after drug exposure [34, 66–68].
The development of CRPC was described to lead to 
increased resistance to docetaxel also in chemotherapy-
naïve patients, suggesting that an intrinsic chemoresistance 
may be present in tumors even before drug exposure 
[69–71]. Chemotherapy effectively induces death of the 
bulk of proliferating tumor cells and concomitantly results 
in the enrichment of cell populations characterized by a 
higher intrinsic resistance, such as CSCs, considered 
major responsible for the poor prognosis of patients 
with cancer [25, 69, 72]. In line with this possibility, 
our findings suggest that aggressive tumor cells with 
increased expression of PTOV1, ALDH1A1, and CCNG2 
might correspond to potential CSCs with great capacity to 
metastasize and higher resistance to docetaxel.
The analyses of public datasets containing data 
from untreated patients, do not confirm the statistically 
significant correlation of PTOV1 with ABCB1, TUBB4A, 
TUBB2B, NANOG, POU5F1, and LIN28A found in the 
cell line models. This lack of correlation might be related 
Table 1: Co-occurrence of DNA alterations in metastatic CRPC
Gene A Gene B p-Value Log odds ratio
PTOV1 ALDH1A1 <0.001 2.338
CCNG2 ALDH1A1 <0.001 2.554
ALDH1A1 MYC <0.001 >3
PTOV1 MYC 0.003 1.591
CCNG2 MYC 0.056 1.155
PTOV1 CCNG2 0.065 1.191
The table shows the quantification (log odds ratio) of how strongly the presence of an alteration in gene A is associated with 
an alteration in the gene B analyzed from published datasets from Beltran et al. [52]. Log odds>0: association towards co-
occurrence. p-value <0.05.
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to the metastatic origin of the cell lines from CRPC 
patients, a more advanced tumor stage compared to the 
untreated tumors included in the data base [31, 73]. In 
addition, the known heterogeneous genetic profiles of 
prostate tumors may not allow to discern those alterations 
found in isolated cells, that may be present in specific 
subsets of tumors but become undetectable in a large 
heterogeneous cohort [58, 74].
PTOV1 action was previously found associated to 
cell cycle progression of prostate cancer cells [9]. Here, we 
show its critical role for the survival of docetaxel-resistant 
cells. PTOV1 is an activator of protein synthesis and its 
function might be crucial in the G2 phase of the cell cycle 
before mitosis when there is a need for a rapid synthesis 
of proteins required for cell division [10]. In addition, the 
activation of Snail1 expression by PTOV1 [10] might be 
linked to its action in the development of resistance to 
docetaxel [29, 30]. These results support that cells arrested 
at the end of the G2 phase in PTOV1 knockdowns are 
unable to bypass the DNA damage checkpoint and enter a 
programmed cell death.
All together our findings indicate that PTOV1 
confers prostate cancer cells the advantages to survive 
docetaxel toxicity, through upregulation of ABCB1 and 
genes associated to docetaxel resistance and pluripotency 
factors. Our study identifies PTOV1, ALDH1A1 and 
CCNG2 as potential markers of metastasis and bad 
prognosis when detected in primary prostate tumors. 
Although further validations are required in additional 
models, our data reveal that blocking PTOV1 might 
be a valid future option to prevent the development of 
resistance to docetaxel in CRPC.
MATERIALS AND METHODS
Cell lines, cell cultures and reagents
HEK293T, human prostate adenocarcinoma LNCaP, 
Du145 and PC3 cells lines were purchased from the 
American Type Culture Collection, Manassas, VA, USA. 
The docetaxel resistant cell lines Du145 and PC3 were 
developed as previously described [31]. HEK293T were 
cultured in DMEM (BioWest, Nuaillé, France), docetaxel 
sentitive and resistant Du145 cells and LNCaP cells 
were cultured in RPMI-1640 (BioWest) and PC3 DS 
and PC3 DR in F12K nutrient mixture medium (Thermo 
Fisher Scientific, Waltham, MA, USA). Culture media 
were supplemented with 10% fetal bovine serum (FBS), 
2 mM l-glutamine, 100 U of penicillin/ml, 100 μg of 
streptomycin/ml, and 0.1 mM non-essential amino acids 
(all from BioWest). Docetaxel resistant cell lines were 
maintained with 2.5 nM of Docetaxel (Sigma-Aldrich, 
St. Louis, MO). Antibody to PTOV1 was produced 
and purified as previously described [8, 9]. Additional 
antibodies were obtained from: goat anti-actin (I-19) 
(Santa Cruz Biotechnology, Santa Cruz, CA); mouse 
anti-HA.11 (16B12) (Covance, MA); mouse anti-Cyclin 
B1(V152) (Abcam, Cambridge, MA); rabbit anti-PARP1 
(H-250) (Santa Cruz Biotechnology). Lentiviral vectors 
carrying short-hairpin RNA (shRNA, TRCN0000143905, 
TRCN0000140104 and TRCN0000139737) to PTOV1 
were obtained from Sigma.
Transfections and transduction
Lentiviral particles were produced in HEK293T by 
cotransfection of lentiviral vectors carrying short hairpin 
RNA (shRNA) or HAPTOV1 templates and plasmids 
encoding gag, pol and env proteins as previously described 
[10].
Plasmids
The lentiviral pHAPTOV1-ires-GFP vector was 
generated by replacing the Luciferase from with 
Hemagglutinin (HA)-tagged human PTOV1, as previously 
described [10]
Protein stability analysis
Cells (3×105 cells/well) were seeded on 6 well 
plates. After 24 h, cells were treated with complete 
medium supplemented with 100 μg/ml cycloheximide 
(Sigma-Aldrich) at indicated times (1, 3, 6, 9 or 15 h). 
Protein extraction and western blotting analysis were 
performed as previously described [53].
Citotoxicity assays
Cells (4×103 cells/well) were seeded on collagen-
coated 96-well plates in sextuplicates. After 24 h, cells 
were control-treated (DMSO) or treated with the drug at 
different concentrations for 48 h for Du145 cells and 72 h 
for PC3 cells. Fresh medium with the drug was replaced 
every day. At the indicated time points, cells were fixed in 
formaldehyde 4% solution, washed with PBS and stained 
with 0.5% crystal violet. Crystals were dissolved with 
15% acetic acid and optical density was read at 595 nm.
Viability assays
Cells, transducted with lentiviral particles during 
24 h, were seeded (5×104 cells/well) on 24-well plates 
in triplicates. After 72 h, cells were collected and stained 
with Trypan blue to identify dead cells. Alive and dead 
cells were counted in a Neubauer chamber.
Spheres formation assay
Single-cells derived from monolayer cultures 
were seeded (3 x 103 cells/well) in 24-well Ultra Low 
Attachment culture plates (Corning Costar, Cambridge, 
MA) in triplicates in 1 ml of DMEM-F12 culture medium 
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(Invitrogen) containing 1% methyl cellulose, 60 μg/ml 
glucose, 1 μM hydrocortisone, 1 μg/ml putrescine, 10 μg/ml 
transferrin, 3 nM sodium selenite, 2.5 ug/ml insulin, 10 ng/ml 
β-FGF, 20 ng/ul, EGF5 U.I./ml heparin (Sigma-Aldrich) 
and 0.4% B27 (Invitrogen). Prostatospheres were fed 
every two days and allowed to grow for 14 days. The 
number of spheres (> 50 cells/sphere) were then counted 
and expressed as ratio of spheres/1000 plated cells (Sphere 
Forming Efficiency, SFE).
Real-time PCR
Total RNA was extracted with the RNeasy mini 
kit (QIAGEN, Valencia, CA), reverse transcribed with 
the RevertAid H Minus First Strand cDNA Synthesis kit 
(ThermoScientific) and real-time qPCR performed with 
the Universal Probe Library (Roche, Penzberg, Upper 
Bavaria, Germany) on a LightCycler 480 RealTime PCR 
instrument (Roche). Primers are shown in Supplementary 
Table 1. The ΔΔCt method was applied to estimate relative 
transcript levels. HMBS amplification levels were used as 
internal references. β-actin amplification levels were used 
as internal references for real-time PCR of polysomes-
bounded RNA. At least three independent experiments 
with triplicate samples were performed. Values are 
presented as mean + SD.
DNA and mRNA analyses in human samples
The mRNA expression data of several genes 
was analyzed in dataset from human prostate tumors 
(GSE46691, n=545; GSE2907, n=95) and breast tumors 
(GSE28844, n=61) using the R2 bioinformatics platform 
(http://r2.amc.nl). The most informative probeset, 
according to its average present signal (APS) and average 
value (Avg) was selected in every dataset, sometimes 
resulting in a different probeset as the choice of R2. DNA 
amplification, point mutations, deletions of the genes of 
interest were analyzed from published datasets of human 
prostate tumors using cBioPortal platform [50, 51].
Western blotting
Western blotting analyses were performed as 
previously described [53]. Specific reactivity to antibodies 
was detected with a chemiluminescent substrate (GE 
Healthcare, Solingen, Germany). Actin or tubulin 
signal was used to monitor protein loading and transfer 
efficiencies.
Cell cycle analysis
One million cells were collected by trypsinization 
and washed twice with PBS. After centrifugation 5 min 
at 300 xG, pellets were resuspended and fixed with 70% 
cold ethanol. Cells were stored overnight at 4ºC. Next, 
cells were pelleted by centrifugation, washed twice with 
cold PBS and resuspended in staining solution, 1 mM 
sodium citrate, 15 μg/ml propidium iodide and 300 μg/ml 
DNAse free RNase A and incubated 4ºC O/N. The samples 
(1 ×106 cells) were analyzed by flow cytometry with a BD 
FacsCalibur device and FlowJo software.
Statistics
All data analyzed were from at least triplicate 
experiments. Results are expressed as means + standard 
deviation of the means. IC50 values for docetaxel 
treatment were determined by non-linear regression. 
For statistical analysis, according to whether data were 
sampled from a Gaussian distribution or not, unpaired t 
test or Mann-Whitney U test was used to compare two 
groups. For multiple comparisons, ANOVA followed 
by Dunnett method or the alternative non parametric 
method (Kruskal-Wallis followed by Dunn method) 
were employed. To quantify the association between 
two quantitative variables, the Spearman correlation was 
used for statistical analysis. The Fisher’s exact test was 
employed to determine whether a nonrandom association 
of co-occurrence between two categorical variables 
was significant. A p value < 0.05 was taken as the level 
of significance. These analyses were performed using 
GraphPad Prism 5 software.
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